AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma
AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma
A multicenter ambispective (retrospective and prospective) non-interventional study of patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with avelumab in France, not impacting the treatment decision made by the treating physician and the medical management of treated patients.
Inclusion Criteria:
Patient ≥ 18 years of age
Patient with locally advanced or metastatic urothelial carcinoma (irrespective of tumor histology) whose disease has not progressed (ongoing stable disease, partial response or complete response) following completion of first-line platinum-based chemotherapy and who has been (retrospective), is (retrospective and prospective), will be (prospective) treated with avelumab.
Patient benefiting from a social security scheme according to local regulations
Exclusion Criteria:
For a patient alive at the moment of the inclusion in the study: patient without liberty, under tutelage, or unable to give oral consent.
Patient enrolled in a prospective interventional clinical trial assessing an investigational product.
Epargny METZ Tessy, 74370, France
Greboble, 38043, France